New combination therapy shows positive Phase III results in lung cancer

New combination therapy shows positive Phase III results in lung cancer

Hutchmed has reported positive Phase III SANOVO trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in patients with EGFR-mutated non-small cell lung cancer and MET overexpression.

Compared with TAGRISSO alone, the combination significantly delayed disease progression.

📊 Key results:

1. the risk of disease progression or death was reduced by 44%;
2. median progression-free survival was 24.9 months, compared with 13.8 months with TAGRISSO alone;
3. in patients with high MET levels, the risk reduction reached 55%;
4. median overall survival was 44.5 months versus 34.9 months;
5. three-year survival rates were 67.4% versus 47.4%.

This is a biomarker-guided treatment approach, meaning therapy is selected based on specific molecular features of a patient’s tumour, including EGFR mutation and MET expression.

Experts say testing for MET at diagnosis could help identify patients who may benefit most from this combination.